All 1 tracked stories fall under one category: pharma. Of the tracked stories, 1 of 1 also mention Aurobindo Pharma Ltd., the most common co-covered peer. The tracked stories average 2 original sources each. Lannett Company LLC appears in 1 tracked Biotech story from July 27, 2026.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Lannett Company LLC
All 1 tracked stories fall under one category: pharma. Of the tracked stories, 1 of 1 also mention Aurobindo Pharma Ltd., the most common co-covered peer. The tracked stories average 2 original sources each. Lannett Company LLC appears in 1 tracked Biotech story from July 27, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 16 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Lannett Company LLC. Shared-story counts are live from our verified record — not editorial picks.
The U.S. Federal Trade Commission approved Aurobindo Pharma USA’s $250 million acquisition of Lannett Company LLC, clearing the final regulatory hurdle.
Aurobindo Pharma’s US subsidiary receives FTC clearance for its $250 million cash-free acquisition of Lannett, adding a complex generics and controlled substances portfolio expected to be immediately accretive to EPS and generate significant synergies.